CompoAtlas

Prostate One

Prostate One, licence 80058826: active licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.

Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.

Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)

Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)

Natural health product licensed in Canada

Licence holder
Canadian Phytopharmaceuticals Corporation
NPN or DIN-HM
80058826
Status
Active licence
Licence date
16 March 2015
Revision date
Not provided
Form
Capsule
Route of administration
Orale
Application type
Officinale

If this product were sold in France

A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.

Composition

Medicinal ingredient and sourcePer dosage unit, according to the sourceMaximum per day, adult
Serenoa repens

Source : Serenoa repens - fruit

320.0 milligrammeNot calculated
Serenoa repens

Source : Serenoa repens - fruit

Potency : 95.0 % Fatty acids

Not specifiedNot calculated
Serenoa repens

Source : Serenoa repens - fruit

Extract : Matériel brut sec

Extraction ratio : 12.000:1

Dry plant equivalent : 3840 milligramme

Not specifiedNot calculated

Non-medicinal ingredients

Sorbitol, Gélatine, Oxydes de fer, Eau, Glycérine

PopulationAgeQuantity per servingFrequency
Adultes de sexe masculinNot specified1.0 Capsule1.0 Jour(s)

Uses authorised in Canada

Text supplied in English because no French text is available.

Used in Herbal Medicine to help relieve the urologic symptoms (e.g. weak urine flow, incomplete voiding, frequent daytime and night time urination) associated with mild to moderate benign prostatic hyperplasia.

A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.

Warnings in Canada

No French warning text available in the imported data.

Warnings are available in English on the official record.

Source

Official Health Canada record, licence 80058826

The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.

The evidence date of this ingredient list is unknown.

Has the product changed? Photograph the packaging.

Enter to analyse, Shift+Enter for a new line